NCT01852370View on ClinicalTrials.gov

Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 20, 2013

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions
Severe Combined Immunodeficiency (SCID)Immunodeficiency With Predominant T-cell Defect, UnspecifiedSevere Chronic NeutropeniaChronic Granulomatous Disease (CGD)Hyper IgE SyndromesHyper IgM DeficienciesWiskott-Aldrich SyndromeMendelian Susceptibility to Mycobacterial DiseaseCommon Variable Immune Deficiency (CVID)
Interventions
BIOLOGICAL

CD3/CD19 negative allogeneic hematopoietic stem cells

Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection and given at time no less than 8 weeks post lung transplant.

Trial Locations (1)

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

All Listed Sponsors
lead

Paul Szabolcs

OTHER